Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Clear all
Completed Phase 1Phase 2 Interventional Results available

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361
View directory record Official record
Conditions
Sepsis
Interventions
Ketamine, Normal Saline placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

NCT01287897
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-04236921 SC injection
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
98
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 30, 2026, 6:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

NCT01143480
View directory record Official record
Conditions
Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance, Cancer
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

Curcumin in Pediatric Inflammatory Bowel Disease

NCT00889161
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions
Curcumin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Results available

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

NCT02960854
View directory record Official record
Conditions
Severe Sepsis
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Sacramento, California • Colorado Springs, Colorado • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 30, 2026, 6:06 AM EDT
Not yet recruiting Not applicable Interventional

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

NCT07811180
View directory record Official record
Conditions
Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis
Interventions
13C6-Glucose
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 6:06 AM EDT
Completed No phase listed Observational

Can CT Enteroclysis Predict the Outcome of Crohn's Disease

NCT00572780
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 30, 2026, 6:06 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of a Nutritional Intervention for Endometriosis

NCT07090096
View directory record Official record
Conditions
Endometriosis
Interventions
A whole food plant based diet
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.

NCT01659762
View directory record Official record
Conditions
Crohn's Disease
Interventions
autologous mesenchymal stromal cell
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04677179
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

NCT02652546
View directory record Official record
Conditions
HIV, Inflammation
Interventions
Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

NCT02367183
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 30, 2026, 6:06 AM EDT
Recruiting No phase listed Observational

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT01904188
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions
Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
2
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 6:06 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

NCT06607003
View directory record Official record
Conditions
Malaria
Interventions
P. vivax challenge agent derived from PvHMB-CCE001
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions
Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated No phase listed Observational

Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

NCT01640886
View directory record Official record
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
MicroPhage, Inc.
Industry
Eligibility
18 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Tuscon, Arizona • Los Angeles, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Not applicable Interventional Results available

Evaluation of PillCam® Express Capsule Endoscopy Delivery System

NCT01088646
View directory record Official record
Conditions
Small Bowel Disease, Inflammatory Bowel Disease
Interventions
PillCam® Express Capsule Endoscopy Delivery System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
2 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Huntsville, Alabama • Montgomery, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional

Imuran Dosing in Crohn's Disease Study

NCT00113503
View directory record Official record
Conditions
Crohn's Disease
Interventions
Azathioprine weight-based dose, Azathioprine individualised dose
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 30, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Early Metabolic Resuscitation for Septic Shock

NCT03895853
View directory record Official record
Conditions
Multiple Organ Failure, Septic Shock, Severe Sepsis
Interventions
Best Practice, early metabolic resuscitation
Other · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 30, 2026, 6:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Aronia on Inflammation and the Gut Microbiome

NCT04128839
View directory record Official record
Conditions
Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions
Aronia berry juice, Sham comparator
Dietary Supplement · Other
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 30, 2026, 6:06 AM EDT